Harmonic Discovery GTM brain

Harmonic Discovery develops precision multi-target therapeutics and collaborates with drug discovery partners on complex diseases.

category

AI-enabled precision drug discovery

market profile

  • text: Kinase medicines can be limited by toxic off-target activity and disease resistance pathways.
  • text: The company combines computational chemistry and experiments in therapeutic discovery and co-development.

personas

  • title: VP of discovery biology at a pharma company
    pains:
    • Single-target candidates miss mechanisms of resistance
    • Needs evidence that target combinations are biologically relevant
  • title: Head of medicinal chemistry
    pains:
    • Optimizing activity across a target panel while avoiding toxic anti-targets
    • Long design cycles and limited experimental data
  • title: Biotech business development leader
    pains:
    • Finding complementary partners for differentiated oncology assets
    • Structuring research collaboration around validated targets and shared milestones

icp

  • text: Pharma and biotech organizations with discovery programs in cancer or other complex diseases and capacity to co-develop small molecules.
  • text: Discovery organizations with differentiated disease biology or kinase targets but a need for medicinal chemistry and multi-target design expertise.

message pillars

  • text: Design medicines that address complex disease biology.
  • text: Use generative chemistry to reduce unwanted target activity.
  • text: Use multi-target design to address efficacy, toxicity and resistance.

objections

  • objection: Can computational predictions translate into viable therapeutics?
    response: Review experimental validation, selectivity profiles and program-specific data before committing to a collaboration.
  • objection: How would the collaboration divide scientific work?
    response: Define each party's target, chemistry and validation contributions and intellectual property terms during diligence.

competitors

  • name: Atomwise
    why: AI-powered structure-based small molecule discovery competes for discovery partnerships.
  • name: Isomorphic Labs
    why: AI-driven drug design company competes for research partnerships and therapeutic programs.

influencers

  • name: Rayees Rahman
    url: https://www.harmonicdiscovery.com/team
    why: Co-founder and CEO involved in discovery and partnerships.

keywords

  • multi target drug discovery
  • kinase selectivity prediction
  • targeted polypharmacology
  • generative chemistry drug discovery
  • kinase inhibitor discovery
  • AI drug discovery partnership

voice

  • Scientific
  • Aspirational
  • Mechanism-focused

signals

  • text: A biotech announces a novel cancer target but needs chemistry capabilities to develop a candidate.
  • text: A discovery team identifies off-target toxicity or resistance as a program constraint.

stack

  • AlphaFold2
  • graph neural networks

pricing

model: unknown

motion

sales_led

channels

  • Scientific publications
  • Partnerships
  • Industry press

confidence

medium

Founders

  • name: Rayees Rahman
    title: Founder/CEO
    role: CEO
    bio: Scientist and startup founder
  • name: Marcel Patek
    title: Founder
    role: Founder
    bio: I am a chemist with training in Medicinal, Organic, Computational, and Peptide chemistry. In my 25+ years in the field, I carried out drug discovery projects involving small molecules and peptides. I worked in environments of startup and global large pharma companies where I led teams and departments in all aspects of early drug discovery. I currently focus on merging experience-based knowledge of molecular optimization with ML/AI systems.

Back to YC companies